礼来日本公司宣布将斥资200亿日元对神户制铁所生产基地进行扩建，旨在显著提升其医药产品生产能力。这项重大投资将用于引进先进生产设备、优化现有产线并扩大厂区规模，以满足市场对创新药物日益增长的需求。
通过此次产能扩张，礼来将进一步加强其在糖尿病、阿尔茨海默病等关键治疗领域的全球供应链稳定性。神户制铁所作为礼来在亚洲的重要战略生产基地，其升级改造将同步采用自动化与数字化技术，确保药品生产质量符合国际最高标准。
该投资计划预计于2025年前完成设备安装与调试工作，届时基地的年产能将提升约30%。此次扩产不仅将巩固礼来在日本医药市场的领先地位，更将为亚太地区患者提供更可持续的药品供应保障。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.